Related references
Note: Only part of the references are listed.Antifungal Resistance Trends of Candida auris Clinical Isolates in New York and New Jersey from 2016 to 2020
Shannon Kilburn et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)
Reverse Transcription-Quantitative Real-Time PCR (RT-qPCR) Assay for the Rapid Enumeration of Live Candida auris Cells from the Health Care Environment
Bryanna Lexus Freitas et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2022)
Factors Associated With Candida auris Colonization and Transmission in Skilled Nursing Facilities With Ventilator Units, New York, 2016-2018
John Rossow et al.
CLINICAL INFECTIOUS DISEASES (2021)
So Many Diagnostic Tests, So Little Time: Review and Preview of Candida auris Testing in Clinical and Public Health Laboratories
Emily K. Dennis et al.
FRONTIERS IN MICROBIOLOGY (2021)
Retrospective Analysis of the Clinical Characteristics of Candida auris Infection Worldwide From 2009 to 2020
Shan Hu et al.
FRONTIERS IN MICROBIOLOGY (2021)
In Vitro Antifungal Resistance of Candida auris Isolates from Bloodstream Infections, South Africa
Tsidiso G. Maphanga et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
Integrated genomic, epidemiologic investigation of Candida auris skin colonization in a skilled nursing facility
Diana M. Proctor et al.
NATURE MEDICINE (2021)
Notes from the Field: Transmission of Pan-Resistant and Echinocandin-Resistant Candida auris in Health Care Facilities ― Texas and the District of Columbia, January–April 2021
Meghan Lyman et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)
In Vitro Evaluation of Antifungal Drug Combinations against Multidrug-Resistant Candida auris Isolates from New York Outbreak
Brittany O'Brien et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Pan-resistant Candida auris isolates from the outbreak in New York are susceptible to ibrexafungerp (a glucan synthase inhibitor)
Y. C. Zhu et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Laboratory Analysis of an Outbreak of Candida auris in New York from 2016 to 2018: Impact and Lessons Learned
YanChun Zhu et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2020)
Candida auris Isolates Resistant to Three Classes of Antifungal Medications — New York, 2019
Belinda Ostrowsky et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2020)
Candida aurisoutbreak involving liver transplant recipients in a surgical intensive care unit
Nicole M. Theodoropoulos et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2020)
Ibrexafungerp: A Novel Oral Triterpenoid Antifungal in Development for the Treatment of Candida auris Infections
Mahmoud Ghannoum et al.
ANTIBIOTICS-BASEL (2020)
Pan-resistant Candida auris: New York subcluster susceptible to antifungal combinations
Brittany O'Brien et al.
LANCET MICROBE (2020)
Multidrug-Resistant Candida auris Infections in Critically III Coronavirus Disease Patients, India, April-July 2020
Anuradha Chowdhary et al.
EMERGING INFECTIOUS DISEASES (2020)
Case-Case Comparison ofCandida aurisVersus OtherCandidaSpecies Bloodstream Infections: Results of an Outbreak Investigation in Colombia
Diego H. Caceres et al.
MYCOPATHOLOGIA (2020)
Molecular Epidemiology of Candida auris in Colombia Reveals a Highly Related, Countrywide Colonization With Regional Patterns in Amphotericin B Resistance
Patricia Escandon et al.
CLINICAL INFECTIOUS DISEASES (2019)
Sentinel Case of Candida auris in the Western United States Following Prolonged Occult Colonization in a Returned Traveler from India
Michael H. Woodworth et al.
MICROBIAL DRUG RESISTANCE (2019)
In Vitro Antifungal Combination of Flucytosine with Amphotericin B, Voriconazole, or Micafungin against Candida auris Shows No Antagonism
A. L. Bidaud et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Detection of Candida auris Antifungal Drug Resistance Markers Directly from Clinical Skin Swabs
Milena Kordalewska et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Global epidemiology of emerging Candida auris
Johanna Rhodes et al.
CURRENT OPINION IN MICROBIOLOGY (2019)
Hospital-Associated Multicenter Outbreak of Emerging Fungus Candida auris, Colombia, 2016
Paige A. Armstrong et al.
EMERGING INFECTIOUS DISEASES (2019)
On the Origins of a Species: What Might Explain the Rise of Candida auris?
Brendan R. Jackson et al.
JOURNAL OF FUNGI (2019)
Epidemiologic Shift in Candidemia Driven by Candida auris, South Africa, 2016-2017
Erika van Schalkwyk et al.
EMERGING INFECTIOUS DISEASES (2019)
Development and Validation of a Real-Time PCR Assay for Rapid Detection of Candida auris from Surveillance Samples
L. Leach et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2018)
Understanding Echinocandin Resistance in the Emerging Pathogen Candida auris
Milena Kordalewska et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
MARDy: Mycology Antifungal Resistance Database
Anthony Nash et al.
BIOINFORMATICS (2018)
A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009-17) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance
Anuradha Chowdhary et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Trichoderma polysporum selectively inhibits white-nose syndrome fungal pathogen Pseudogymnoascus destructans amidst soil microbes
Amanpreet Singh et al.
MICROBIOME (2018)
Multiple introductions and subsequent transmission of multidrug-resistant Candida auris in the USA: a molecular epidemiological survey
Nancy A. Chow et al.
LANCET INFECTIOUS DISEASES (2018)
A Candida auris Outbreak and Its Control in an Intensive Care Setting
David W. Eyre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Genomic insights into multidrug-resistance, mating and virulence in Candida auris and related emerging species
Jose F. Munoz et al.
NATURE COMMUNICATIONS (2018)
Candida auris in Healthcare Facilities, New York, USA, 2013-2017
Eleanor Adams et al.
EMERGING INFECTIOUS DISEASES (2018)
Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses
Shawn R. Lockhart et al.
CLINICAL INFECTIOUS DISEASES (2017)
Candida auris candidaemia in Indian ICUs: analysis of risk factors
Shivaprakash M. Rudramurthy et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
In Vitro Activity of a Novel Glucan Synthase Inhibitor, SCY-078, against Clinical Isolates of Candida auris
Elizabeth L. Berkow et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
SCY-078 Is Fungicidal against Candida Species in Time-Kill Studies
Bernard Scorneaux et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Acquired Flucytosine Resistance during Combination Therapy with Caspofungin and Flucytosine for Candida glabrata Cystitis
Caroline Charlier et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
First report of Candida auris in America: Clinical and microbiological aspects of 18 episodes of candidemia
Belinda Calvo et al.
JOURNAL OF INFECTION (2016)
Investigation of the First Seven Reported Cases of Candida auris, a Globally Emerging Invasive, Multidrug-Resistant Fungus - United States, May 2013-August 2016
Snigdha Vallabhaneni et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2016)
Draft genome of a commonly misdiagnosed multidrug resistant pathogen Candida auris
Sharanya Chatterjee et al.
BMC GENOMICS (2015)
Multilaboratory Testing of Antifungal Drug Combinations against Candida Species and Aspergillus fumigatus: Utility of 100 Percent Inhibition as the Endpoint
Ping Ren et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Candidemia caused by amphotericin B and Fluconazole resistant Candida auris
S. Sarma et al.
INDIAN JOURNAL OF MEDICAL MICROBIOLOGY (2013)
Facultative Sterol Uptake in an Ergosterol-Deficient Clinical Isolate of Candida glabrata Harboring a Missense Mutation in ERG11 and Exhibiting Cross-Resistance to Azoles and Amphotericin B
Claire M. Hull et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
In vitro Etest synergy of doripenem with amikacin, colistin, and levofloxacin against Pseudomonas aeruginosa with defined carbapenem resistance mechanisms as determined by the Etest method
Wendy He et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2012)
Multilaboratory Testing of Two-Drug Combinations of Antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis
Vishnu Chaturvedi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Mutational Analysis of Flucytosine Resistance in Candida glabrata
Thomas D. Edlind et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Nonsense and Missense Mutations in FCY2 and FCY1 Genes Are Responsible for Flucytosine Resistance and Flucytosine-Fluconazole Cross-Resistance in Clinical Isolates of Candida lusitaniae
Martine Florent et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Candida auris sp nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital
Kazuo Satoh et al.
MICROBIOLOGY AND IMMUNOLOGY (2009)
Molecular mechanism of flucytosine resistance in Candida lusitaniae: Contribution of the FCY2, FCY1, and FUR1 genes to 5-fluorouracil and fluconazole cross-resistance
Nicolas Papon et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Molecular mechanisms of primary resistance to flucytosine in Candida albicans
WW Hope et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Flucytosine-fluconazole cross-resistance in purine-cytosine permease-deficient Candida lusitaniae clinical isolates:: Indirect evidence of a fluconazole uptake transporter
T Noël et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Expression profiling of the response of Saccharomyces cerevisiae to 5-fluorocytosine using a DNA microarray
L Zhang et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2002)
Comparison of Etest, chequerboard dilution and time-kill studies for the detection of synergy or antagonism between antifungal agents tested against Candida species
RE Lewis et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2002)
Share Paper
